Purity, aggregation state, and target binding are critical quality requirements that need to be monitored throughout the antibody development cycle as they impact product efficacy and safety. Yet, ...

Antibodies hold promise as therapeutic agents. However, their tendency to aggregate poses significant challenges to drug development. In a groundbreaking study, researchers now provide novel insights ...

Download this handbook to learn more about the capabilities of mass photometry for evaluating antibody aggregation and binding. When experiments refuse to cooperate, you try again and again. For ...

Antibodies (immunoglobulins) are Y-shaped proteins that recognize and neutralize specific pathogens. Their ability to target specific molecules or cells has made them promising candidates for future ...

Antibody-based therapeutics rely on advanced bioanalytical techniques throughout development and production to ensure the safety, efficacy, and consistent performance of the final product. A key ...

INDIANAPOLIS – (June 4, 2024) – Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, continues its mission to reduce workflow times and grueling manual steps with ...

Scientists from the University of Ghent say they have developed new techniques for assessing antibody stability during drug development to select formulations that minimize degradation during ...

Monoclonal antibodies are highly specific for their antigen and have a well-characterized structure, making them ideal for use as antibody therapeutics. 5 Each mAb, composed of two heavy and two light ...

Ikoma, Japan – Antibodies (immunoglobulins) are Y-shaped proteins that recognize and neutralize specific pathogens. Their ability to target specific molecules or cells has made them promising ...